Floatz logo

Tazemetostat

Advanced Solid Tumors (Phase 1)

Epizyme, Inc.Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Advanced Solid Tumors (Phase 1) cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Epizyme, Inc.
Phase 1/2CCC
Nk Cell Preparation
Guangzhou Xiling Biotechnology Co., Ltd.
Phase 1CC
lnf2007
Shandong New Time Pharmaceutical Co., LTD
Phase 1NR

Same molecule, other indications

Tazemetostat is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
epithelioid sarcomaDormant
BB
Indicative ·
70 / 100
View asset →
kidney medullary carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →